Jay T. Backstrom
About
Jay T. Backstrom is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Jay T. Backstrom has authored 46 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 28 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Jay T. Backstrom's work include Acute Myeloid Leukemia Research (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers) and Hemoglobinopathies and Related Disorders (9 papers). Jay T. Backstrom is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers) and Hemoglobinopathies and Related Disorders (9 papers). Jay T. Backstrom collaborates with scholars based in United States, France and United Kingdom. Jay T. Backstrom's co-authors include David R. McKenzie, Lewis R. Silverman, Pierre Fenaux, Alan F. List, Eva Hellström‐Lindberg, Valeria Santini, Ghulam J. Mufti, John F. Seymour, Steven D. Gore and C.L. Beach and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.
In The Last Decade
Jay T. Backstrom
46 papers receiving 3.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jay T. Backstrom United States | 14 | 3.2k | 1.7k | 1.0k | 638 | 417 | 46 | 3.8k | ||
| C.L. Beach United States | 15 | 3.0k 0.9× | 1.6k 1.0× | 894 0.9× | 651 1.0× | 363 0.9× | 67 | 3.5k | ||
| Carlo Finelli Italy | 28 | 3.2k 1.0× | 1.7k 1.0× | 1.7k 1.7× | 434 0.7× | 286 0.7× | 108 | 4.1k | ||
| Norbert Gattermann Germany | 26 | 3.6k 1.1× | 1.7k 1.0× | 1.6k 1.5× | 672 1.1× | 318 0.8× | 55 | 4.5k | ||
| Michael Pfeilstöcker Austria | 22 | 1.9k 0.6× | 594 0.3× | 942 0.9× | 284 0.4× | 115 0.3× | 83 | 2.3k | ||
| Jalaja Potluri United States | 27 | 2.7k 0.8× | 1.6k 0.9× | 1.4k 1.4× | 651 1.0× | 175 0.4× | 79 | 3.7k | ||
| Erin P. Demakos United States | 10 | 1.4k 0.4× | 1.0k 0.6× | 474 0.5× | 275 0.4× | 203 0.5× | 31 | 1.9k | ||
| Toshiko Motoji Japan | 26 | 1.5k 0.5× | 915 0.5× | 700 0.7× | 366 0.6× | 104 0.2× | 121 | 2.6k | ||
| Rosalie Odchimar-Reissig United States | 9 | 1.4k 0.4× | 1.0k 0.6× | 434 0.4× | 275 0.4× | 205 0.5× | 25 | 1.9k | ||
| Preben Philip Denmark | 25 | 1.8k 0.5× | 978 0.6× | 628 0.6× | 879 1.4× | 99 0.2× | 69 | 2.8k | ||
| Nicoletta Testoni Italy | 35 | 3.7k 1.1× | 1.5k 0.9× | 1.9k 1.8× | 676 1.1× | 48 0.1× | 187 | 4.4k |
Countries citing papers authored by Jay T. Backstrom
Since
Specialization
Citations
This map shows the geographic impact of Jay T. Backstrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay T. Backstrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay T. Backstrom more than expected).
Fields of papers citing papers by Jay T. Backstrom
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jay T. Backstrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay T. Backstrom. The network helps show where Jay T. Backstrom may publish in the future.
Co-authorship network of co-authors of Jay T. Backstrom
This figure shows the co-authorship network connecting the top 25 collaborators of Jay T. Backstrom. A scholar is included among the top collaborators of Jay T. Backstrom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay T. Backstrom. Jay T. Backstrom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cappellini, Maria Domenica, Alì Taher, Antonio Piga, et al.. (2023). Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept. European Journal Of Haematology. 111(1). 113–124.
2.
Olíva, Esther Natalie, Uwe Platzbecker, Guillermo Garcia‐Manero, et al.. (2021). Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. Journal of Clinical Medicine. 11(1). 27–27.
3.
Saft, Leonie, Masoud Karimi, Mehran Ghaderi, et al.. (2014). p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 99(6). 1041–1049.
4.
Freeman, John, et al.. (2013). Teratogenic Drugs and Risk Management: An Implementation Assessment. Therapeutic Innovation & Regulatory Science. 48(4). 420–427.
5.
Kuendgen, Andrea, Michael Lauseker, Alan F. List, et al.. (2012). Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 27(5). 1072–1079.
6.
Giagounidis, Aristoteles, Eva Hellström‐Lindberg, Pierre Fenaux, et al.. (2011). 58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients. Leukemia Research. 35. S21–S21.
7.
Santini, Valeria, Pierre Fenaux, Ghulam J. Mufti, et al.. (2010). Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. European Journal Of Haematology. 85(2). 130–138.
8.
Seymour, John F., Pierre Fenaux, Lewis R. Silverman, et al.. (2010). Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology. 76(3). 218–227.
9.
Fenaux, Pierre, Norbert Gattermann, John F. Seymour, et al.. (2010). Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C. British Journal of Haematology. 149(2). 244–249.
10.
Fenaux, Pierre, Ghulam J. Mufti, Eva Hellström‐Lindberg, et al.. (2009). Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology. 28(4). 562–569.
11.
Mufti, Ghulam J., Steven D. Gore, Valeria Santini, et al.. (2009). Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen.. Blood. 114(22). 1755–1755.
12.
Fenaux, Pierre, Ghulam J. Mufti, Eva Hellström‐Lindberg, et al.. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology. 10(3). 223–232.
13.
Hellström‐Lindberg, Eva, Pierre Fenaux, G J Mufti, et al.. (2008). Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status. Journal of Clinical Oncology. 26(15_suppl). 7089–7089.
14.
Santini, Valeria, Pierre Fenaux, Ghulam J. Mufti, et al.. (2008). Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA).. Blood. 112(11). 1653–1653.
15.
Younes, Anas, Michelle A. Fanale, Barbara Pro, et al.. (2007). A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. Journal of Clinical Oncology. 25(18_suppl). 8000–8000.
16.
Lyons, Roger M., Thomas M. Cosgriff, Sanjiv Modi, et al.. (2006). Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.. Blood. 108(11). 2662–2662.
17.
Silverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, et al.. (2006). Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 24(24). 3895–3903.
18.
Silverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, et al.. (2005). Rates of Infection and Bleeding Are Not Increased in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine Compared with Supportive Care.. Blood. 106(11). 2525–2525.
19.
Lyons, Roger M., et al.. (2005). Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).. Blood. 106(11). 2517–2517.
20.
Isom, Harriet C. & Jay T. Backstrom. (1979). Aberrant regulation of ornithine decarboxylase by serum, putrescine, and spermidine in cytomegalovirus-transformed human cells.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 39(3). 864–9.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by C.L. Beach Breakdown of academic impact, for papers by Carlo Finelli Breakdown of academic impact, for papers by Norbert Gattermann Breakdown of academic impact, for papers by Michael Pfeilstöcker Breakdown of academic impact, for papers by Jalaja Potluri Breakdown of academic impact, for papers by Erin P. Demakos Breakdown of academic impact, for papers by Toshiko Motoji Breakdown of academic impact, for papers by Rosalie Odchimar-Reissig Breakdown of academic impact, for papers by Preben Philip Breakdown of academic impact, for papers by Nicoletta Testoni